Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00872092
Other study ID # BTO-0001
Secondary ID
Status Completed
Phase N/A
First received March 30, 2009
Last updated March 30, 2009
Start date October 1997
Est. completion date September 1998

Study information

Verified date March 2009
Source University Hospital, Bonn
Contact n/a
Is FDA regulated No
Health authority Germany: Ethics Commission
Study type Observational

Clinical Trial Summary

Normally the gastrointestinal tract is only sparsely colonized with bacteria. The normal flora of the duodenal or jejunal aspirate contains no more than 10^5 bacteria per milliliter. Small bowel bacterial overgrowth (SBBO) is defined as a pathologically increased number of bacteria or the presence of colonic flora in the proximal intestine. The reasons for this condition are manifold, ranging from diabetic neuropathy to surgical bypass. SBBO is frequent in elderly people. Therapy is targeted at correcting the underlying small bowel abnormalities that predispose to the condition and at providing appropriate antibiotic therapy. The symptoms and signs of SBBO can be reversed with this approach. However, in many patients the conditions predisposing to SBBO persist life-long, once present. This suggests that noninvasive, sensitive diagnostic tools with high specificity are required. Bacterial culture of upper intestinal content is considered the diagnostic gold standard. However, since endoscopic harvesting of duodenal or jejunal fluid is difficult and invasive, indirect tests such as breath tests have been advocated as diagnostic tools. Hydrogen breath tests are commonly employed since the substrates can be easily obtained and the measurement is simple. Hydrogen is formed when carbohydrates are fermented in the intestine. Breath hydrogen analysis allows a separation of metabolic activity of the intestinal flora from that of the host, since no known hydrogen production occurs in mammalian tissue. The hydrogen breath test most often used in routine clinical practice uses glucose. However, the utility of this test is mostly limited by its low sensitivity, because there are "nonproducers" in up to 25% of the subjects tested. The investigators have developed a stable isotope breath test using 13C-labeled lactose-ureide. Glycosyl-ureides are condensation products of reducing sugars and urea in aqueous acid. Lactose-[13C]ureide has been used to investigate oro-caecal transit time because it resists digestion by small intestinal enzymes and is hydrolyzed by bacterial enzymes in the large intestine. A number of studies have described the use of this substrate in adults and children. The aim of the present study was to investigate the lactose-[13C]ureide breath test in subjects with suspected SBBO and to compare its results with the results of the glucose hydrogen breath test. Microbiological analyses of upper intestinal bacterial cultures were used as gold standard to identify SBBO.


Recruitment information / eligibility

Status Completed
Enrollment 22
Est. completion date September 1998
Est. primary completion date September 1998
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Suspected small bowel bacterial overgrowth

Exclusion Criteria:

- Age < 18 years

- Antibiotic therapy

Study Design

N/A


Related Conditions & MeSH terms


Intervention

Other:
Stable-isotope labeled lactose ureide breath test
2 g 13C-labeled lactose ureide orally

Locations

Country Name City State
Germany University of Bonn Bonn

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Bonn

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary 13CO2 enrichment in breath CO2 3 hours No
Secondary Hydrogen output in breath 3 hours No
See also
  Status Clinical Trial Phase
Completed NCT00816842 - Plasma Citrulline Concentration in Tropical Enteropathy N/A
Completed NCT00138879 - Citrulline: A Plasmatic Marker to Assess and Monitor Small Bowel Crohn's Disease Patients N/A
Completed NCT03543540 - Bioequivalence Study of Nexvax2 in Subjects With Celiac Disease Phase 1
Recruiting NCT05209568 - Immune Responses to Gluten N/A
Completed NCT01141998 - Vitamin D Substitution for Patients With Chronic Pancreatitis and Malabsorption N/A
Active, not recruiting NCT03644069 - A Study of the Safety, Efficacy and Tolerability of Nexvax-2 in Patients With Celiac Disease (CeD) Phase 2
Completed NCT00662675 - A Study of the Efficacy and Tolerability of Pancrelipase Microtablet (MT) Capsules for the Treatment of Cystic Fibrosis-dependent Exocrine Pancreatic Insufficiency Phase 3
Suspended NCT03462979 - Effects of Home Gluten Immunogenic Peptide Testing on Children With Celiac Disease N/A
Not yet recruiting NCT00163813 - The Early Nasojejunal Tube to Meet Energy Requirements in Intensive Care (ENTERIC) Study N/A